ArticleJournal of biology2008
Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.
Article in Journal of biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 2 syntheses or guidelines pooled it, 305 citations in OpenAlex.
- Effects of Exercise Interventions and Physical Activity Behavior on Cancer Related Cognitive Impairments: A Systematic Review.BioMed research international · 2016Pooled it
- Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Pooled it
- Trial
- Cancer therapy-related cognitive impairment, part 1: an integrative clinical-mechanistic framework from phenotypes to convergent neurobiological pathways.Pharmacological reports : PR · 2026Review
- Functional brain network alterations linked to cancer-related cognitive impairment in breast cancer patients.The oncologist · 2026Article
- Working Memory Impairment Induced by Chemotherapy-A Narrative Review.Brain sciences · 2026Review
- Chemotherapy-Induced Brain Damage: Mechanisms and Insights from Rodent Models.Brain sciences · 2026Review
- Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026Review
- Chemotherapy neurotoxicity and aging: Uncovering shared central nervous system pathologies and potential interventions.Neuro-oncology advances · 2026Review
- Nanofiber-based platform for quantitative analysis of human oligodendrocyte ensheathment with pharmacological perturbations.Stem cell reports · 2026Article
- The potential of microbiome modulators to improve quality of life in cancer survivors through gut microbiome-immune interactions.Frontiers in molecular neuroscience · 2026Review
- Quercetin and 5-Fluorouracil Synergistically Suppress ZEB1 and Restore Epithelial Integrity in Triple-Negative Breast Cancer.Iranian biomedical journal · 2026Article
- Article
- Article
- Microglia-Mediated Synaptic Dysfunction Contributes to Chemotherapy-Related Cognitive Impairment.Journal of neurochemistry · 2025Article
- Enhanced anticancer activity of novel pyrimidine nucleoside analog in pancreatic cancer.American journal of cancer research · 2025Article
- Synergistic Potential of Argentatins A and B to Improve 5-Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models.Journal of cellular and molecular medicine · 2024Article
- Neurocognitive Functioning of Patients with Sinonasal and Nasopharyngeal Cancers Treated With Multimodality Therapy.Journal of neurological surgery. Part B, Skull base · 2024Article
- Molecular Actions ofAnti-cancer agents in medicinal chemistry · 2024Article
- Fluorouracil-induced leukoencephalopathy mimicking neuroleptic malignant syndrome: a case report.Journal of medical case reports · 2023Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCancer treatment with a variety of chemotherapeutic agents often is associated with delayed adverse neurological consequences. Despite their clinical importance, almost nothing is known about the basis for such effects. It is not even known whether the occurrence of delayed adverse effects requires exposure to multiple chemotherapeutic agents, the presence of both chemotherapeutic agents and the body's own response to cancer, prolonged damage to the blood-brain barrier, inflammation or other such changes. Nor are there any animal models that could enable the study of this important problem.
resultsWe found that clinically relevant concentrations of 5-fluorouracil (5-FU; a widely used chemotherapeutic agent) were toxic for both central nervous system (CNS) progenitor cells and non-dividing oligodendrocytes in vitro and in vivo. Short-term systemic administration of 5-FU caused both acute CNS damage and a syndrome of progressively worsening delayed damage to myelinated tracts of the CNS associated with altered transcriptional regulation in oligodendrocytes and extensive myelin pathology. Functional analysis also provided the first demonstration of delayed effects of chemotherapy on the latency of impulse conduction in the auditory system, offering the possibility of non-invasive analysis of myelin damage associated with cancer treatment.
conclusionsOur studies demonstrate that systemic treatment with a single chemotherapeutic agent, 5-FU, is sufficient to cause a syndrome of delayed CNS damage and provide the first animal model of delayed damage to white-matter tracts of individuals treated with systemic chemotherapy. Unlike that caused by local irradiation, the degeneration caused by 5-FU treatment did not correlate with either chronic inflammation or extensive vascular damage and appears to represent a new class of delayed degenerative damage in the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.